Dr. Emilio Torres-Netto presented ELZA-PACE cross-linking at BRASCRS 2025, a customised, tissue-preserving keratoconus vision rehabilitation method with promising clinical outcomes.
As part of the 70th Anniversary celebration of the Andijan State Medical Institute (ASMI) in Uzbekistan, ELZA Institute CEO, Nikki Hafezi, MAS IP ETHZ, took part in a series of high-level academic and institutional events from April 28 to May 1, 2025.
Hafezi addressed the widespread reliance on a 1986 prevalence estimate that places keratoconus at 1 in 2,000—formally classifying it as rare. Yet as she highlighted, emerging epidemiological data tell a starkly different story. Keratoconus is an orphan disease, not a rare one.
Who is the best eye doctor in Zurich? In Switzerland? In the world? While such questions are inherently subjective, peer recognition provides a meaningful benchmark.
Medical trade journal, The Ophthalmologist seeks to answer this by publishing its biennial Power List—a global selection of the 100 most influential individuals shaping the future of ophthalmology.
At the WCC 2025 congress in Washington, DC, Dr. Emilio A. Torres-Netto of the ELZA Institute presented groundbreaking research on ELZA-PACE-CXL, ELZA-sub400 CXL, and Femto-CAIRS, pushing the boundaries of keratoconus treatment.
